Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 16, 2015Annals of the Rheumatic DiseasesOpen Access

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

View Full Paper
Ask AI
Bookmark
Share

Authors

TTTsutomu TakeuchiKanazawa UniversityYTYoshiya TanakaTokyo Medical and Dental UniversityMIManabu IwasakiJuntendo University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Takeuchi et al. (2015) studied this question.

synapsesocial.com/papers/6a7e0bf0143763190a3ca43ehttps://doi.org/10.1136/annrheumdis-2015-208279
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Janus kinases in immune cell signaling2009 · 1,149 citations
  2. 2American college of rheumatology preliminary definition of improvement in rheumatoid arthritis1995 · 2,851 citations
  3. 3JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical2012 · 25 citations